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Quantitative 3D scintigraphy shows
increased muscular uptake of
pyrophosphate in idiopathic
inflammatory myopathy
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Abstract
Background: Nuclear imaging is increasingly being used in the diagnostic work-up of idiopathic inflammatory
myopathy (IIM). Increased muscular uptake of technetium-99m-pyrophosphate (99mTc-PYP) has hitherto been
assessed qualitatively by planar scintigraphy. We set out to perform quantitative tomographic scintigraphy in IIM.
Results: Ninety IIM patients and 48 control subjects underwent 99mTc-PYP single-photon emission computed
tomography (SPECT)/CT of the upper and lower body. Scans were evaluated visually by an intensity score (1–4)
and quantitatively by the mean standardized uptake value (SUVmean) in thigh muscles after semi-automated
segmentation of these. Furthermore, a SUVmean gradient down along the thighs was determined by linear
regression of the slice-by-slice activity. Interobserver analyses were performed on qualitative evaluations. Compared
to controls, patients more often had a high intensity score (p < 0.0001), but interobserver analyses revealed only
moderate agreement. The thigh muscular 99mTc-PYP activity (SUVmean) was 60% higher in patients than in controls,
p < 0.0001, albeit with a wide range. There was an activity gradient down the thigh muscle, the proximal tracer
uptake being highest, and this gradient was steeper in patients than in controls; the activity decreased by 0.
00024 and 0.00010 SUVmean mm
−1, respectively, along the thighs.
Conclusions: The muscular uptake of 99mTc-PYP was significantly higher in patients than in healthy controls
by qualitative and quantitative assessment. The tracer uptake was higher in the proximal than in the distal
part of the thigh muscle, and SUVmean gradients differed between groups. Hence, tomographic nuclear
imaging allowing for quantification of the 99mTc-PYP uptake might contribute to the diagnosis of IIM, and
SPECT/CT of the lower body might suffice.
Keywords: Quantitative SPECT, PYP, Myositis, SPECT/CT
Background
Idiopathic inflammatory myopathies (IIMs) constitute a
group of heterogeneous, rare, systemic diseases charac-
terized by inflammation in skeletal muscles [1]. The inflam-
mation causes progressive, symmetrical muscle weakness
and can be invalidating. The most common subsets of IIMs
are polymyositis (PM), dermatomyositis (DM), and sporadic
inclusion body myositis (sIBM). IIMs affect the hip and
shoulder girdle muscles, the proximal part of the muscles
of the extremities, and the neck muscles. In all cases, in-
flammation can include different organs. Especially, cardiac
affection, lung involvement, and the increased risk of
cancer in DM patients result in an increased mortality and
morbidity [2–6]. PM and DM usually respond to anti-
inflammatory drugs [7], and early diagnosis and treatment
can limit disease progression [8].
Bohan and Peter have set up diagnostic criteria for
IIM [9, 10]. These include elevated serum values of
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muscle enzymes, pathologic muscle biopsy, pathologic
electromyography, proximal and symmetrical muscle
weakness, and for dermatomyositis characteristic skin
symptoms. However, a high frequency of false negative
muscle biopsies has been reported, which might be due
to the patchy nature of IIM. Imaging may help to
visualize if muscles are affected diffusely or focally,
optimize biopsy location, aid diagnosis in cases where
muscle biopsy is not feasible, and monitor the disease.
Different imaging modalities have been tested, primarily
magnetic resonance imaging (MRI) and ultrasound
[11–15]. Within the field of nuclear imaging, multiple
tracers have been used for detection of muscle affection
[16–18]. One is technetium-99m-pyrophosphate
(99mTc-PYP), a bone tracer, which by planar imaging
was found to show increased uptake in inflamed mus-
cles [19, 20] judged by visual comparison with uptake
in bones [21]. We investigated 99mTc-PYP single-
photon emission computed tomography (SPECT) with
attenuation correction and anatomical localization by
computed tomography (CT) enabling a quantitative as-
sessment of the tracer uptake in the muscles of patients
with PM or DM.
Methods
As part of a cross-sectional, observational study on 90
patients with PM/DM described previously and focusing
on cardiac disease [22, 23], 99mTc-PYP uptake in skeletal
muscles was compared to the muscular uptake in 48
healthy controls. Briefly, patients aged ≥ 18 years with
definite (N = 56) or probable (N = 34) PM/DM according
to the Bohan and Peter criteria [9, 10] participated in
the study. All except one patient with antisynthetase
syndrome had a muscle biopsy performed at the time of
diagnosis. All muscle biopsies but six showed typical
histological abnormalities with mononuclear inflammatory
infiltrates and varying degrees of necrosis, degeneration,
regeneration, and atrophy. The six patients without in-
flammation in the biopsy had the presence of myositis-
specific autoantibodies and/or a rash (heliotrope rash and/
or Gottron’s sign). Patients were newly diagnosed, un-
treated myositis patients (termed acute, N = 14) or long-
standing myositis patients (termed chronic, N = 76).
Scintigraphy
For the purpose of scintigraphy, 550 MBq of 99mTc-PYP
was administered intravenously. Imaging was performed
on a Siemens Symbia T16 SPECT/CT scanner with low-
energy high-resolution collimators with a 15% window
centered on the 140 keV photo peak of 99mTc. All acute
patients had a whole-body scan 10 min p.i. as described
in previous protocols [24]. All patients and controls
underwent SPECT/CT of the thorax (arms along the
body except in one case), and all but one acute patient
had SPECT/CT of the pelvis and thighs 3 h p.i. SPECT
parameters were 64 projections, 128 × 128 matrix, 40 s/
frame at the upper body, and 20 s/frame at the lower
body; the lower body scan was accomplished as a two-
bed acquisition. CT was performed as a low-dose non-
contrast-enhanced scan (130 kV, 20 mAs). SPECT data
were reconstructed iteratively (four iterations, four sub-
sets) with scatter and attenuation correction as well as
resolution recovery and postfiltered with an 8-mm
Gaussian filter. Three-dimensional models (maximum
intensity projections) were interpreted visually and
transaxial slices quantitatively. Since the investigators
themselves collected data, they were not blinded at the
time of scintigraphy, but data processing was performed
later without looking at the clinical data. Unfortunately,
the postponement of the processing resulted in a loss of
data for some of the participants.
Qualitative evaluation
A qualitative assessment of tracer uptake including in-
tensity, pattern, and symmetry was performed for both
the upper and lower body in patients and controls.
Images were analyzed on the GE Xeleris workstation
(GE Healthcare Denmark, Brøndby, Denmark). First,
two readers (KT and JS) evaluated scans by consensus
(first observation). Prompted by previous scoring sys-
tems for planar 99mTc-PYP images with focus on tracer
uptake of cardiac tissue relative to that of the ribs [21],
we graded peripheral muscular uptake compared to up-
take in adjacent bones from 1 to 4 (1 = uptake predom-
inantly in bone, 2 = bones >> soft tissue,
3 = bones ≥ soft tissue, and 4 = bones < soft tissue).
Tracer uptake pattern was considered patchy in case of
distinct spots with high uptake in muscles. Scans were
described as asymmetrical if hot spots were seen on one
side only and symmetrical if the muscular tracer uptake
was diffuse or if hot spots were equally found on both
sides. Later, a third reader (KB-O) evaluated a subset of
the scans at a separate time point with the purpose of
testing reproducibility (second observation). This reader
was completely blinded to the clinical data.
Quantitative evaluation
Tracer uptake was measured in bilateral thigh muscles
after semi-automated delineation based on CT scans as
illustrated in Fig. 1. Siemens Inveon Research Workplace
software (Siemens Healthcare, Ballerup, Denmark) was
used to manually define upper and lower demarcation
lines 5 cm below the trochanter major and 8 cm above
the knee joint, respectively. Within the volume in be-
tween these demarcation lines, automated thresholding
segmentation based on Hounsfield units (HU) was ap-
plied. Voxels with values within the range 200–2000 HU
were defined as bone. Considering the spatial resolution
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of SPECT, 15 mm was then added to the bone volume
in all directions in order to avoid spillover from bone
uptake into the muscle volume. Voxel values within the
range 0–90 HU were defined as muscle. The rather wide
range of muscle HU values was chosen in light of a high
noise level of the low-dose CT and varying fatty infiltra-
tions of muscles of patients and healthy subjects. Feasi-
bility of automated segmentation of muscles of the
right-sided upper limb, shoulder girdle, and neck was
also tested for in a small subset of patients and controls.
Demarcation lines were placed right below the chin
and at the elbow level. Again, voxels with values within
the range 200–2000 HU were considered as bone and
after expansion by 15 mm in all directions omitted
from the volume of interest (VOI). Contrary to results
for the lower limbs, however, voxel values within the
range 0–90 HU were insufficient in defining muscles,
probably due to higher noise levels. Including voxels
with values within 0–150 HU yielded a fair delineation
of the muscles judged visually.
The mean number of counts per voxel (cps mL−1) in
each VOI was registered, and the mean voxel activity
(Bq mL−1) was calculated from the knowledge of the
camera sensitivity (cps MBq−1). Camera sensitivity was
measured using a known amount of 99mTc [25]. The
activity was decay corrected according to the time of in-
jection and normalized to injected activity (MBq) per
body weight (kg) of the participant. The result was a
mean standardized uptake value (SUVmean) measured in
grams per milliliter. Based on a linear fit of the slice-by-
slice SUVmean down along each subject’s thigh muscles,
a gradient (g mL−1 mm−1) was assessed.
Statistics
Results are presented as frequencies (percentages) for
categorical variables and descriptive statistics like mean
(range) or mean ± standard error of the mean (SEM) for
continuous variables, supplemented by 95% confidence
intervals (95% CI) when appropriate. Differences in fre-
quency distributions were compared by Fisher’s exact
test or the chi-square test. Intergroup differences in con-
tinuous variables were tested by the unpaired Student’s t
test or the Wilcoxon rank-sum test. The correlation be-
tween ordinal variables was assessed by means of Spear-
man’s rho. Results from interobserver analyses were
reported as proportions of agreement and reliability in
terms of weighted kappa (Cicchetti-Allison weights [26])
with bootstrapped 95% CI according to the guidelines
proposed by Kottner et al. [27]. Univariate linear regres-
sion was used to explore the relationship between the
SUVmean and clinical parameters of disease activity ac-
cording to the International Myositis Assessment and
Clinical Study Group (IMACS) [28]. Goodness of fit of
the model was assessed with the R-squared statistics.
The significance level was set at 5%. Statistical analyses
were performed using Stata/IC 11.2 (©StataCorp LP,
College Station, TX, USA).
Results
Patients and controls did not differ significantly in age
or body constitution, although the body mass index of
patients tended to be higher than that of controls. The
majority was female with no intergroup difference
(Table 1).
Qualitative analyses
Early whole-body scans showed diffuse activity in soft
tissue and organs corresponding to the perfusion of
these and were judged not to contribute to the diagnosis
of IIM.
Figure 2 shows examples of scintigraphy after 3 h,
demonstrating tracer uptake in the soft tissue of a pa-
tient (right side of Fig. 2a, b), whereas in a control per-
son, mainly the skeleton is visualized (left side of Fig. 2a,
b). Figure 2c illustrates the patchy muscular uptake of a
patient.
Results from the visual interpretation of the tracer up-
take are shown in Table 2. According to the first obser-
vation, the median upper limb intensity score was 2 in
Fig. 1 Volume of interest (VOI) encompassing bilateral thigh muscles.
a Transaxial slice. b Coronal slice
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patients and 1 in controls. According to the second ob-
servation, it was 3 and 1, respectively. From the first ob-
servation, the median lower limb intensity score was 2
in both groups with different distributions; in patients,
the majority scored 2, whereas in the control group, fre-
quencies of scores 1 and 2 were nearly equal, and a min-
imal number scored higher than 2. From the second
observation, the median lower limb score was 2 and 1,
respectively. Intergroup comparisons of the intensity
scores of upper and lower extremities showed that high
scores were significantly more prevalent in patients
than in controls (p < 0.0001) in both observations. The
correlation between upper and lower limb scores was
0.64 in patients and 0.63 in controls in the first obser-
vation and 0.57 versus 0.71 in the second observation,
respectively (p for all < 0.005). The first observers found
more patients than controls to have a patchy distribu-
tion of scintigraphic activity (24 vs. 6% for the upper
limbs, p = 0.01; 22 vs. 6% for the lower limbs, p = 0.03),
while the second observer almost never concluded
patchiness. There was no significant difference in the
symmetry/asymmetry of the tracer uptake between pa-
tients and controls according to any of the observers.
Qualitative parameters did not differ between PM and
DM patients or between sexes (data not shown).
The proportion of agreement between observers was
0.54 [0.40;0.67] for the upper limb score and 0.50
[0.37;0.63] for the lower limb score. Kappa was 0.53
[0.37;0.69] (p < 0.0001) for the upper limb score and
0.47 [0.30;0.64] (p < 0.0001) for the lower limb score.
Considering dichotomized scores (1 or 2 vs. 3 or 4),
the proportion of agreement was 0.84 [0.71;0.92] for
both upper and lower limb scores; kappa was 0.65
[0.43;0.88] (p < 0.0001) for the upper limb score and
0.59 [0.34;0.83] (p < 0.0001) for the lower limb score.
Quantitative analyses
Semi-automated quantification was done in 83 patients
and 46 controls. Results are shown in Fig. 3 and in Table
3. The SUVmean of patients was 60% higher than that of
the controls with no overlap between 95% confidence in-
tervals. Ranges were, however, wide and overlapping
(Fig. 3, upper row). In patients, the decrease of activity
down along the thigh was 2.5 times than that of the con-
trol subjects (Fig. 3, lower row). Muscular 99mTc-PYP
uptake and activity gradient did not differ between PM
and DM patients (data not shown). There were no dif-
ferences in 99mTc-PYP uptake according to sex, whereas
Table 1 Clinical characteristics of patients with polymyositis or
dermatomyositis and control persons
All patients
(N = 90)
Controls
(N = 48)
p value
Age (years) 60.3 ± 1.3 59.9 ± 1.2 0.82
Body weight (kg) 78.7 ± 1.9 74.7 ± 1.8 0.13
Height (m) 1.70 ± 0.01 1.69 ± 0.01 0.87
Body mass index 27.3 ± 0.6 25.9 ± 0.4 0.06
Female, N (%) 57 (63) 32 (67) 0.71
PM/DM, N (%) 60 (67)/30 (33)
MMT8, 0–80 72.5 ± 0.8
HAQ, 0–3 0.68 ± 0.08
MD global activity, VAS 0–10 cm 2.64 ± 0.25
PA global activity, VAS 0–10 cm 4.92 ± 0.31
CK relative valuea 2.99 ± 0.75
MMT8: each of eight muscle groups scored 0–10; lower scores indicate
reduced strength. HAQ, MD and PA global activity: higher scores indicate
more severe disease activity
PM polymyositis, DM dermatomyositis, MMT8 manual muscle test including
eight muscle groups, HAQ Health Assessment Questionnaire, MD physician,
VAS visual analogue scale, PA patient
aThe value of creatine kinase divided by the local upper reference value
Fig. 2 Maximum intensity projection images showing the distribution
of 99mTc-PYP. a Upper body of a control person (left) and a patient
with idiopathic inflammatory myopathy (right). b Lower body of a
control person (left) and a patient with idiopathic inflammatory
myopathy (right). In the control person, bones are clearly delineated,
whereas in the patient, the muscular and the skeletal uptake are
confluent. c Examples of an irregular 99mTc-PYP uptake leading to hot
spots in the muscles of a patient with idiopathic inflammatory
myopathy. Hot spots are marked with red arrows
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women had a steeper gradient than men (− 0.00025
SUV mm−1 vs. − 0.00001 SUV mm−1, p = 0.0002). The
muscular 99mTc-PYP activity of patients correlated with
clinical parameters of disease activity; the manual muscle
test including eight muscle groups (MMT8), the Health
Assessment Questionnaire (HAQ), physician global activ-
ity using a 10-cm visual analogue scale (VAS), and patient
global activity, but not with the serum level of creatine
kinase (Table 4).
Semi-automated quantification of the right-sided mus-
cles of the upper body was done in nine patients and
eight controls and revealed results similar to those of
the lower body. Ratios between lower and upper body
SUVs were 1.2 in patients and 1.1 in controls (p = 0.16),
and in spite of the small sample, results from the upper
body also differed significantly between patients and
controls (SUVmean 0.29 [0.22;0.36] vs. 0.21 [0.19;0.23],
p = 0.02).
Seeing that the group of patients was heterogeneous,
we did an exploratory comparison of the muscular up-
take of acute patients with that of chronic patients as
well—well aware of the inequality in size of these subsets
(quantitative data available in 13 vs. 70 patients). The
SUVmean did not differ between patient groups (0.36
[0.32;0.40] in the acute vs. 0.34 [0.31;0.36] in the chronic,
p = 0.17). The gradient was significantly steeper in acute
than in chronic patients (− 0.00044 [− 0.00061;− 0.00027]
vs. − 0.00021 [− 0.00027;− 0.00014], p = 0.01).
Discussion
Diagnosis and classification of IIM make quite a chal-
lenge. Diagnostic imaging might be helpful and has been
experimented with for several years. From the present
scintigraphic material, we found significantly higher
muscular 99mTc-PYP uptake in patients with PM/DM
than in controls by means of both qualitative and
Table 2 Qualitative parameters of 99mTc-PYP muscular uptake in patients with polymyositis or dermatomyositis and control persons
Upper limbs Lower limbs
A. First observation
All patients (N = 87) Controls (N = 48) p value All patients (N = 85) Controls (N = 47) p value
Intensity score
1 24 (28) 34 (71) < 0.0001 14 (16) 22 (47) < 0.0001
2 34 (39) 10 (21) 50 (59) 24 (51)
3 23 (26) 4 (8) 17 (20) 1 (2)
4 6 (7) 0 (0) 4 (5) 0 (0)
Patchy pattern
Yes 21 (24) 3 (6) 0.01 19 (22) 3 (6) 0.03
No 66 (76) 45 (94) 66 (78) 44 (94)
Symmetry
Yes 71 (82) 45 (94) 0.07 70 (82) 44 (94) 0.11
No 16 (18) 3 (6) 15 (18) 3 (6)
B. Second observation
All patients (N = 25) Controls (N = 25) p value All patients (N = 25) Controls (N = 25) p value
Intensity score
1 7 (28) 19 (76) < 0.0001 8 (32) 19 (76) < 0.0001
2 3 (12) 3 (12) 5 (20) 6 (24)
3 6 (24) 3 (12) 7 (28) 0 (0)
4 9 (36) 0 (0) 5 (20) 0 (0)
Patchy pattern
Yes 0 (0) 1 (4) 1.00 0 (0) 0 (0) 1.00
No 25 (100) 24 (96) 25 (100) 25 (100)
Symmetry
Yes 25 (100) 24 (96) 1.00 25 (100) 25 (100) 1.00
No 0 (0) 1 (4) 0 (0) 0 (0)
Number of observations (%)
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quantitative assessments, which might suggest this im-
aging technique as a potential, valuable diagnostic tool
in IIM.
The qualitative evaluation did not allow for a cutoff
value between the two groups; however, the distribution
in the groups differed significantly. Patients quite often
scored 3, which was seldom in the control group, and
sometimes 4, which was never found in the control
group. Hence, high scores may be indicative of IIM. In
theory, a patchy scintigraphic appearance may be indica-
tive of IIM and might even be suggestive of where to
perform a biopsy [15, 29]. Due to single hot spots, asym-
metrical tracer uptake tended to occur more often in
our patients; all in all, however, a symmetrical appear-
ance was far the most common. This is in line with the
clinical symptoms of symmetrical muscle weakness as
well as with previous scan findings [30]. Compared to
previous studies using planar scintigraphy with purely
visual interpretation [21, 24], SPECT/CT images can be
read quantitatively and, hence, have the potential to object-
ively distinguish physiology from pathophysiology. Muscle
segmentation can be performed semi-automatically with
consequential elimination of observer bias. Quantification
of the muscular tracer uptake revealed higher values in pa-
tients than in controls with no overlap in 95% CI. Further-
more, results allowed for calculation of a 99mTc-PYP
gradient down along the thigh muscle that was more pro-
nounced in acute compared to chronic patients and espe-
cially compared to controls which supports the idea of
using SPECT/CT as a complementary diagnostic tool in
the primary diagnosis of IIM.
The possibility to quantify an emission signal is usually
associated with positron emission tomography (PET)/
CT, in which the tracer uptake in SUVs can be read
directly from the images [30]. SPECT/CT is also a quanti-
tative modality [25]. In any circumstance, the application
Fig. 3 Muscular 99mTc-PYP uptake in thigh muscles of patients with idiopathic inflammatory myopathy versus controls. Upper row: SUVmean.
Lower row: 99mTc-PYP gradient. Left column: all patients versus controls. Right column: chronic patients, acute patients, and controls. Boxes show
median and upper and lower quartiles. Whiskers mark the highest value within the 3rd quartile + 1.5 times the interquartile range (IQR) and the
lowest value within the 1st quartile − 1.5 IQR, whereas observations being either larger or smaller than those were defined as outliers and plotted
as individual points
Table 3 Results of semi-automated quantification of thigh muscles in patients with polymyositis or dermatomyositis and control
persons
All patients (N = 83) Controls (N = 46) p value
Estimate 95% CI Min–max Estimate 95% CI Min–max
SUVmean 0.34 [0.32;0.36] 0.15–0.73 0.21 [0.20;0.22] 0.14–0.29 < 0.0001
Slope of activity per length
unit of muscle (SUVmean mm
−1)
− 0.00024 [− 0.00030;− 0.00018] − 0.00097 to 0.00047 − 0.00010 [− 0.00013;− 0.00007] − 0.00028 to 0.00014 < 0.0001
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of SUVs is only meaningful when the biodistribution of
the tracer involves the entire body. 99mTc-PYP is probably
distributed within lean body mass alone, and therefore,
the 99mTc-PYP uptake in VOIs of our participants could
be corrected for their body fat percentage, which is, how-
ever, not simply calculated. Still, this is less critical when
comparing uptake in different locations within the same
muscle compartment. Blood and soft tissue tracer uptake
can be assumed to be equal for the entire thigh muscle.
Absolute numbers depend on different patient-related fac-
tors; i.e., the external validity of the present SUVs is com-
promised. Therefore, a relative measure independent of a
scanner technique is warranted. If every patient could be
his own reference, scintigraphy could yield a single num-
ber signifying the degree of affection, which would be
ideal. An index for tracer uptake (i.e., the gradient) within
the thigh muscle might be of diagnostic use. However, this
would require an established general population-based
reference interval with cutoff values which will have to be
addressed in larger cohort studies.
In recent years, PET with 18F-fluorodeoxyglucose
(18F-FDG) has come into use in rheumatologic diseases
including IIM because of the high sensitivity to inflam-
mation [16, 30, 31]. As the basis for our project was
cardiac involvement [22, 23] and there is a naturally
high 18F-FDG uptake in the heart, 18F-FDG was less
suitable in our case. Instead, we used 99mTc-PYP which
was the predominant myopathy marker for years. While
99mTc-PYP is a bone tracer, the muscular uptake in case
of myopathy is often considered to represent inflamma-
tion and regeneration [32]. This notion is supported by
our results showing that muscular 99mTc-PYP uptake of
patients correlated with clinical parameters of disease
activity. Theories on the 99mTc-PYP uptake mechanism
concern calcium salt deposition and formation of com-
plexes with denatured macromolecules, since the tracer
has been found in edema fluid and invading inflammatory
cells as well as in injured muscle fibers [33–35]. As such,
the mechanism is unspecific for IIM but could be relevant
to all inflammatory muscle diseases. Contrary to other in-
flammatory rheumatic diseases, e.g., rheumatoid arthritis,
IIM is characterized by a reduced number of capillaries
and even by some designated as vasculopathy [36]. While
increased blood flow may play a role in the initial 99mTc-
PYP uptake, we believe that the tracer distribution at
steady-state acquisitions reflects muscle injury. Previous
results on the correlation of 18F-FDG and MRI signals
with clinical parameters were ambiguous, probably due to
different characteristics of these modalities [16, 37, 38].
Common to all imaging modalities used in IIM is the lack
of population-based reference intervals.
In the present study, we focused on segmentation of
thigh muscles. A small explorative series indicated no
difference in quantitative results from the upper and
lower body. Likewise, qualitative scores for upper and
lower limbs were correlated, signifying a robustness of
the data but also suggesting that imaging of the lower
body might suffice. This is in line with the practice of
performing MRI of the thighs only [39, 40], just as
muscle biopsy is usually taken from the quadriceps
muscle. Focused SPECT/CT would spare the patients
CT radiation as well as time. Muscles of the thighs are
quite easily defined by semi-automated methods like
ours, whereas automated segmentation of upper limbs is
hampered by various adjacent structures with different
densities. Inclusion of plethoric structures like large ves-
sels might result in higher count rates. Marked athero-
sclerosis, which is overrepresented in several rheumatic
diseases including IIM [41], may lead to a higher uptake
of bone tracers like 99mTc-PYP. Manual masking of the
blood vessels is feasible and seemed, in our case, to in-
crease the SUV difference between patients and controls
but also implies a loss of observer independence. Ratios
between SUVs of the lower and upper body were slightly
above 1 in both patients and controls. A possible ex-
planation is the higher impact of partial volume effect
on the smaller muscles of the upper body. Spillover
from bone uptake should be omitted [32], which is
doable in the thighs and more difficult in the arms.
On the other side, safety margins could result in
falsely lower count rates if hot spots near bones are
abandoned.
Table 4 Results of univariate linear regression analysis of the relation between the SUVmean and clinical parameters of disease
activity
Coefficient 95% CI p value R2
MMT8, 0–80 − 0.005 [− 0.009;− 0.002] 0.002 0.10
HAQ, 0–3 0.05 [0.02;0.08] 0.001 0.14
MD global activity, VAS 0–10 cm 0.01 [0.006;0.02] 0.001 0.12
PA global activity, VAS 0–10 cm 0.01 [0.001;0.02] 0.02 0.07
CK relative valuea 0.003 [− 0.001;0.007] 0.12 0.03
MMT8: each of eight muscle groups scored 0–10; lower scores indicate reduced strength. HAQ, MD, and PA global activity: higher scores indicate more severe
disease activity
MMT8 manual muscle test including eight muscle groups, HAQ Health Assessment Questionnaire, MD physician, VAS visual analogue scale, PA patient
aThe value of creatine kinase divided by the local upper reference value
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Strengths and weaknesses
Previous papers on scintigraphic appearance of IIM were
case reports or presentations of non-controlled, smaller
studies. We collected a large material, and furthermore,
we compared the patients with a control group. The pa-
tients were at different disease stages. We obtained data
systematically from standardized VOIs instead of just
reading the maximum number of counts in affected
areas. Gradients were calculated from simple linear fits,
and we did not elaborate on goodness of fits.
Interobserver analyses revealed some, but far from
perfect, reproducibility of qualitative scores. According
to the reliability measures proposed by Landis and Koch
[42], three of our kappa values could be interpreted as
moderate reliability and the kappa for dichotomized
upper limb scores as substantial reliability. Agreement
parameters [43] in terms of proportion of agreement
were also not striking but somewhat higher when con-
sidering dichotomized results. This shows that a subject-
ive evaluation cannot stand alone but supports the
potential diagnostic value of an interpretation referring
to a low (1 and 2) or a high (3 and 4) 99mTc-PYP uptake
in muscles compared to bone. Interobserver differences
in scores could, in part, be caused by varying the use of
the intensity scale during scan reading since adjustment
of the intensity level could have an impact on the
visualization of bone. The same applies to the judgment
of patchiness on which the different observers in our
groups did not agree. Again, this points to room for
improvement of a qualitative evaluation.
Conclusions
The muscular uptake of 99mTc-PYP was significantly
higher in patients than in healthy controls by means of
both qualitative and quantitative assessments, and the
tracer uptake for upper and lower limbs was correlated.
The tracer distribution within the thighs allowed for an
individual gradient, possibly indicative of the degree of
muscle affection. Our results suggest that 99mTc-PYP
SPECT/CT might be a helpful complementary tool in
the diagnosis of IIM and that lower body acquisitions
may suffice. Establishment of a general population-based
reference interval with cutoff values for 99mTc-PYP
SPECT/CT in larger cohort studies is still warranted.
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